It looks like the FDA had a busy, but steady, 2025. With 46 new drug approvals, the agency stayed right on track with its usual pace, but the real story is in what they approved. We’re seeing a massive shift toward "first-in-class" science and precision medicine for diseases that have been ignored for too long.

Figure 1. 2025 FDA Drug Approvals, source: reference [1]

Here’s a breakdown of the big wins from the past year.

Breaking New Ground: "First-in-Class" Breakthroughs

Nearly half of this year’s approvals—20 drugs, or 43%—were labeled "first-in-class." This means they don't just improve on old drugs; they work via totally new biological pathways. These are the heavy hitters designed for when traditional medicine hits a wall.

Figure 2. First-in-class Drug, source: reference [1]

Blujepa (gepotidacin): This is a huge win for public health. It’s the first new oral antibiotic mechanism for UTIs in almost 30 years. With "superbugs" becoming a major threat, having a new tool for UTIs and gonorrhea is a relief for doctors everywhere.

Journavx (suzetrigine): This could be a game-changer for the opioid crisis. It’s the first new mechanism for treating acute pain in over 20 years, offering a non-opioid option for moderate-to-severe pain.

Brinsupri (brensocatib): It targets the specific inflammation found in non-cystic fibrosis bronchiectasis, a condition that hasn't had many direct treatment options in the past.

Dawnzera (donidalorsen): A new preventive option for those suffering from hereditary angioedema, helping patients stop attacks before they start.

The Rise of "Guided Missiles" in Cancer (ADCs)

Antibody-drug conjugates (ADCs) remain one of the most prominent and rapidly evolving modalities in oncology, and their presence among 2025 FDA approvals reflects the growing maturity of the platform. Think of them as guided missiles: they find the cancer cells and drop a toxic payload exactly where it’s needed, sparing healthy tissue.

Datroway (datopotamab deruxtecan-dlnk): This approval brings ADC tech to patients with HR-positive, HER2-negative breast cancer who have already tried chemo. It targets the TROP2 protein, proving these drugs work for more than just HER2-positive cases.

Emrelis (telisotuzumab vedotin) : This is the first-ever therapy for a specific type of advanced lung cancer (c-Met overexpressing). It’s a textbook example of precision medicine—finding a specific genetic marker and building a drug just for that.

Precision Medicine in Cancer Care

Cancer remains the biggest focus for the FDA. In 2025, the agency prioritized "hard-to-treat" cancers like Acute Myeloid Leukemia and Diffuse Midline Glioma. One of the biggest highlights was the Avmapki + Fakzynja co-pack, which is the first-ever treatment specifically for KRAS-mutated low-grade serous ovarian cancer. It’s another step away from "one-size-fits-all" oncology.

A Record Year for Rare Diseases

Perhaps the most impressive stat from 2025: 50% of all approvals were for rare diseases. Half of the new drugs (23 out of 46) were granted "Orphan Drug" status. This shows a serious commitment to patients who usually get left behind by big pharma.

The FDA greenlit treatments for a wide range of niche conditions, including:

• ● Barth Syndrome
  

• ● Acromegaly
  

• ● Generalized Myasthenia Gravis
  

• ● Idiopathic Pulmonary Fibrosis
  

• ● Hemophilia

The Bottom Line

2025 was a year of balance. The FDA kept the volume steady but dialed up the innovation. By using "accelerated pathways," they’re getting these high-tech treatments to patients faster. We’re moving toward a future where "untreatable" conditions finally have a target on their backs.

Reference:
[1] New Drug Therapy Approvals 2025 https://www.fda.gov/media/190705/download?attachment